A Phase 2, Single-Arm Study of Pralatrexate in Patients With Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary Bladder.
Phase of Trial: Phase II
Latest Information Update: 21 Oct 2014
At a glance
- Drugs Pralatrexate (Primary)
- Indications Bladder cancer
- Focus Therapeutic Use
- Sponsors Spectrum Pharmaceuticals
- 04 Jul 2012 Planned number of patients changed from 41 to 50 as reported by EudraCT.
- 12 Dec 2011 Actual end date (September 2011) added as reported by ClinicalTrials.gov.
- 12 Dec 2011 Actual patient number is 30 added as reported by ClinicalTrials.gov.